Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, today announced ...
Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, May 28, 2026Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a ...
Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason for not taking up its option to bring a MRSA antibiotic into clinical development. Basilea secured the license option ...
(RTTNews) - Switzerland's Basilea Pharmaceutica Ltd. (BPMUF.PK) Thursday announced that its partner Asahi Kasei Pharma Corp. has filed a New Drug Application or NDA for the marketing authorization of ...
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has ...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company, committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...
Basilea Pharmaceutica may finally be able to bring its antibiotic ceftobiprole to the US market – 13 years after its first attempt was turned down – thanks to a new phase 3 clinical trial. The ...
GlaxoSmithKline (GSK) is ending its effort to commercialize Toctino (alitretinoin) in the U.S., nearly four years after buying global rights to the eczema drug from its developer Basilea Pharmaceutica ...
Continued commercial success of Cresemba and Zevtera in 2022 generated revenue contributions of approx. CHF 122 million, exceeding guidance by more than 17% Significant proceeds from oncology ...
ZURICH, Feb 24 (Reuters) - Swiss biotech group Basilea filed a claim against U.S. partner Johnson & Johnson over delays in launching an antibiotic to treat drug-resistant superbugs after the approval ...
(RTTNews) - Basilea Pharmaceutica AG (BPMUF, 0QNA.L), a Swiss commercial-stage biopharmaceutical company, Monday announced its asset purchase agreement with Spexis AG to acquire a preclinical program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results